Screener / SEC EDGAR /CIK 0001104506 /10-K filed Feb 19, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

INSMED Inc INSM

Compare with peers Embed
FY2025 at a glance

Sales up 66.7%, free cash flow down to -$967.6M

XBRL, from each 10-K
RevenueStatements
$606.4M from $363.7M in FY2024
FY2016FY2025
Net incomeStatements
-$1.3B from -$913.8M in FY2024
FY2016FY2025
Free cash flowStatements
-$967.6M from -$705.8M in FY2024
FY2016FY2025
EPS (diluted)Statements
$-6.42 from $-5.57 in FY2024
FY2016FY2025
Operating marginStatements
-205.6% from -241.5% in FY2024
FY2016FY2025
Total debtStatements
$546.8M from $1.1B in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (40)
EPS (ttm)
-2.81
Sales (ttm)
1.5B
Net income (ttm)
-605.6M
Sales growth
+66.7%
EPS growth
-
Sales Q/Q
+268%
Free cash flow
-627.6M
Gross margin
84.4%
Oper. margin
-37.1%
Net margin
-39.9%
FCF margin
-41.3%
R&D / sales
127.2%
Dividend
-
Debt/Eq
0.75
Curr. ratio
2.86
Cash
396.6M
Op. cash flow (ttm)
-595.6M
EBITDA
-1.2B
EBITDA margin
-203.9%
Net debt
150.2M
Quick ratio
2.64
Interest cover
-14.88
FCF after stock pay
-1.1B
Goodwill / assets
6.0%
Oper. margin low 5y
-241.5%
Stock pay / sales
25.2%
Shares out.
219.4M
Shares Y/Y
+21.3%
Book / share
3.31
Cash / share
1.81
Sales / share
6.93
Asset turnover
0.68
Inventory turns
0.93
Days sales out.
85
Sales 3Y CAGR
+35.2%
Sales 5Y CAGR
+29.8%
Employees
1,664
Sales / employee
913K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 606.4M Net income -1.3B
FY2016 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0001104506-19-000009 FY2016 net income -176.3M · NetIncomeLoss, 0001104506-19-000009 0 FY2016 FY2017 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0001104506-20-000007 FY2017 net income -192.6M · NetIncomeLoss, 0001104506-20-000007 0 FY2017 FY2018 revenue 9.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001104506-21-000005 FY2018 net income -324.3M · NetIncomeLoss, 0001104506-21-000005 9.8M FY2018 FY2019 revenue 136.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001104506-22-000008 FY2019 net income -254.3M · NetIncomeLoss, 0001104506-22-000008 136.5M FY2019 FY2020 revenue 164.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001104506-23-000009 FY2020 net income -294.1M · NetIncomeLoss, 0001104506-23-000009 164.4M FY2020 FY2021 revenue 188.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001104506-24-000008 FY2021 net income -434.7M · NetIncomeLoss, 0001104506-24-000008 188.5M FY2021 FY2022 revenue 245.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001104506-25-000009 FY2022 net income -481.5M · NetIncomeLoss, 0001104506-25-000009 245.4M FY2022 FY2023 revenue 305.2M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001104506-26-000009 FY2023 net income -749.6M · NetIncomeLoss, 0001104506-26-000009 305.2M FY2023 FY2024 revenue 363.7M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001104506-26-000009 FY2024 net income -913.8M · NetIncomeLoss, 0001104506-26-000009 363.7M FY2024 FY2025 revenue 606.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001104506-26-000009 FY2025 net income -1.3B · NetIncomeLoss, 0001104506-26-000009 606.4M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing.

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share -3.5% a year FY2015 $5.32 to FY2025 $3.71, 10 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 -$6.42$3.71-$4.86
Dec 31, 2024 -$5.57$1.74-$4.30
Dec 31, 2023 -$5.34-$2.36-$3.91
Dec 31, 2022 -$3.91$0.71-$3.33
Dec 31, 2021 -$3.88$3.66-$3.31
Dec 31, 2020 -$3.01$2.83-$2.31
Dec 31, 2019 -$3.01$3.09-$3.46
Dec 31, 2018 -$4.22$2.71-$3.53
Dec 31, 2017 -$2.89$5.42-$2.44
Dec 31, 2016 -$2.85$2.50-$2.44
Dec 31, 2015 -$2.02$5.32-$1.78

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $1.8B
  • − All liabilities $1.5B
  • = Net current asset value $268.6M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $739.0M
  • − Goodwill $136.1M
  • − Other intangible assets $97.7M
  • = Tangible book value $505.2M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

INSM against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+66.7%10th of 155 · median +10.5%
Net margin
-4.1%15.3%
-39.9%136th of 154 · median 6.8%
Return on equity
-5.2%18.5%
-83.4%140th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
-41.3%132nd of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
0.7563rd of 108 · median 0.69
INSM and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
INSM INSMED Inc$1.5B +66.7%84.4%-39.9%-83.4%-41.3%0.75
MMSI Merit Medical Systems Inc$1.6B +11.8%49.4%9.9%9.2%12.6%0.42
LNTH Lantheus Holdings, Inc.$1.6B +0.5%61.3%17.3%19.9%-0.42
PEN Penumbra Inc$1.6B +17.5%68.0%10.1%9.9%12.8%-
LIVN LivaNova PLC$1.5B +10.7%67.8%13.0%14.3%8.6%0.22
ADUS Addus HomeCare Corp$1.5B +23.2%32.3%7.4%9.4%9.6%0.02
All 162 companies in the group

Where the $606.4M of revenue came from

by product, year to Dec 31, 2025

  • ARIKAYCE $433.8M · 72%
  • BRINSUPRI $172.7M · 28%

From the segment tables in the 10-K XBRL.

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity -172.8% FY2020: -106.6% net income ÷ equity
Net margin -210.5% FY2020: -178.9% profit per $ of sales: -1.3B ÷ 606.4M
Asset turnover 0.27× FY2020: 0.21× sales per $ of assets: 606.4M ÷ 2.3B
Leverage 3.06× FY2020: 2.89× assets per $ of equity: 2.3B ÷ 739.0M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -39.9% vs 6.8%
  • Return on equity below 15%
    -83.4%
  • A profit in 0 of 10 years
Net margin, FY2016 to FY2025: -3297.2% to -210.5%

Balance sheet

  • Interest covered less than 5 times
    Operating income is -14.9× interest expense
  • Debt smaller than equity
    Debt / equity 0.75 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 2.86
  • More cash than debt
    Net cash $769.4M
Debt / equity at each year end, FY2016 to FY2025: 0.36 to 0.74

Cash and shareholders

  • Free cash flow positive in 0 of 10 years
    −$967.6M last year
  • Share count up over 5 years
    +103.9%
Free cash flow, FY2016 to FY2025: -150.9M to -967.6M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$546.8M of principal due, schedule of Sep 30, 2026

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

INSM's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue606.4M
FY2016: 0FY2017: 0FY2018: 9.8MFY2019: 136.5MFY2020: 164.4MFY2021: 188.5MFY2022: 245.4MFY2023: 305.2MFY2024: 363.7MFY2025: 606.4M FY2017FY2019FY2021FY2023FY2025
Net income-1.3B
FY2016: -176.3MFY2017: -192.6MFY2018: -324.3MFY2019: -254.3MFY2020: -294.1MFY2021: -434.7MFY2022: -481.5MFY2023: -749.6MFY2024: -913.8MFY2025: -1.3B FY2017FY2019FY2021FY2023FY2025
Free cash flow-967.6M
FY2016: -150.9MFY2017: -162.6MFY2018: -271.1MFY2019: -292.9MFY2020: -225.6MFY2021: -370.6MFY2022: -410.3MFY2023: -549.5MFY2024: -705.8MFY2025: -967.6M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay-1.1B
FY2016: -168.9MFY2017: -180.7MFY2018: -297.3MFY2019: -319.9MFY2020: -261.7MFY2021: -416.6MFY2022: -468.0MFY2023: -624.3MFY2024: -802.6MFY2025: -1.1B FY2017FY2019FY2021FY2023FY2025
EPS (diluted)-6.42
FY2016: -2.85FY2017: -2.89FY2018: -4.22FY2019: -3.01FY2020: -3.01FY2021: -3.88FY2022: -3.91FY2023: -5.34FY2024: -5.57FY2025: -6.42 FY2017FY2019FY2021FY2023FY2025
Diluted shares199.0M
FY2016: 61.9MFY2017: 66.6MFY2018: 76.9MFY2019: 84.6MFY2020: 97.6MFY2021: 112.1MFY2022: 123.0MFY2023: 140.4MFY2024: 164.0MFY2025: 199.0M FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
ARIKAYCE 433.8M71.5% +19.3%
BRINSUPRI 172.7M28.5% -

10-K 0001104506-26-000009, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
US 453.0M74.7% +77.8%
International 153.5M25.3% +40.9%

10-K 0001104506-26-000009, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue009.8M136.5M164.4M188.5M245.4M305.2M363.7M606.4M
Cost of revenue002.4M24.2M39.9M44.2M55.1M65.6M85.7M122.9M
Gross profit-07.4M112.3M------
R&D122.7M109.7M145.3M131.7M181.2M272.7M397.5M571.0M598.4M771.1M
SG&A50.7M79.2M168.2M210.8M203.6M234.3M265.8M344.5M461.1M701.2M
Operating income-173.4M-188.9M-307.3M-235.2M-265.2M-375.1M-457.3M-709.6M-878.3M-1.2B
Interest expense3.5M5.9M25.5M27.7M29.6M40.5M26.4M81.7M84.9M83.8M
Pretax income-176.2M-192.9M-324.1M-253.6M-292.7M-436.4M-480.2M-747.0M-910.1M-1.3B
Income tax98K-272K201K777K1.4M-1.8M1.4M2.6M3.7M5.0M
Net income-176.3M-192.6M-324.3M-254.3M-294.1M-434.7M-481.5M-749.6M-913.8M-1.3B
EPS (diluted)-2.85-2.89-4.22-3.01-3.01-3.88-3.91-5.34-5.57-6.42
Diluted shares61.9M66.6M76.9M84.6M97.6M112.1M123.0M140.4M164.0M199.0M
Depreciation & amortization2.4M2.9M3.6M5.2M9.1M9.1M5.3M5.5M6.0M10.4M
EBITDA-171.0M-186.0M-303.7M-230.0M-256.1M-366.0M-452.0M-704.1M-872.3M-1.2B
Gross margin--75.4%82.3%------
Operating margin---3124.9%-172.4%-161.3%-199.0%-186.4%-232.5%-241.5%-205.6%
Net margin---3297.2%-186.4%-178.9%-230.6%-196.3%-245.6%-251.2%-210.5%
Revenue growth---+1288%+20.5%+14.6%+30.2%+24.4%+19.2%+66.7%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-146.7M-159.6M-258.0M-250.6M-219.3M-363.3M-400.4M-536.2M-683.9M-935.0M
Capital spending4.2M3.0M13.1M42.3M6.2M7.3M9.9M13.3M21.9M32.6M
Free cash flow-150.9M-162.6M-271.1M-292.9M-225.6M-370.6M-410.3M-549.5M-705.8M-967.6M
Stock-based pay (added back)18.0M18.1M26.2M27.0M36.2M46.0M57.7M74.8M96.8M152.7M
Free cash flow after stock pay-168.9M-180.7M-297.3M-319.9M-261.7M-416.6M-468.0M-624.3M-802.6M-1.1B
Acquisitions---006.7M00--
Debt raised30.0M00-------
Debt repaid0057.8M00-----
Investing cash flow-4.2M-3.0M-14.8M-42.3M-6.8M-64.3M-34.6M-223.6M-583.2M-64.6M
Financing cash flow30.7M381.1M386.7M285.3M271.0M612.5M793.3M168.4M1.3B954.1M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)18.0M18.1M26.2M27.0M36.2M46.0M57.7M74.8M96.8M152.7M
Stock-based pay / revenue--266.8%19.8%22.0%24.4%23.5%24.5%26.6%25.2%
Operating lease cost---12.2M8.7M12.1M12.9M10.4M10.4M10.9M
Operating lease cash paid---10.1M8.8M14.6M11.4M9.1M10.4M11.0M
Finance lease principal paid---0936K1.1M601K1.2M2.6M3.0M
Right-of-use assets---37.7M32.9M33.3M21.9M18.0M17.3M20.7M
Operating lease liabilities---40.3M32.7M31.0M21.8M19.0M18.5M21.6M
Finance lease liabilities---20.8M15.8M14.7M30.9M29.6M27.0M24.1M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/INSM/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.